These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21972227)

  • 21. New targets for cancer chemotherapy.
    Murgo AJ; Dancey J; Eckhardt SG; Hidalgo M; Arbuck SG; Zerivitz K; Blaylock BA
    Cancer Chemother Biol Response Modif; 2002; 20():239-72. PubMed ID: 12703208
    [No Abstract]   [Full Text] [Related]  

  • 22. Selective antagonism of anticancer drugs for side-effect removal.
    Fernández A; Sessel S
    Trends Pharmacol Sci; 2009 Aug; 30(8):403-10. PubMed ID: 19595465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.
    Baumann M; Krause M; Dikomey E; Dittmann K; Dörr W; Kasten-Pisula U; Rodemann HP
    Radiother Oncol; 2007 Jun; 83(3):238-48. PubMed ID: 17502118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of c-Raf-1: therapeutic implications.
    Beeram M; Patnaik A; Rowinsky EK
    Clin Adv Hematol Oncol; 2003 Aug; 1(8):476-81. PubMed ID: 16258435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assays for in vitro and in vivo synergy.
    Teicher BA
    Methods Mol Med; 2003; 85():297-321. PubMed ID: 12710216
    [No Abstract]   [Full Text] [Related]  

  • 27. Reactive oxygen species may have antitumor activity in metastatic melanoma.
    Tuma RS
    J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
    [No Abstract]   [Full Text] [Related]  

  • 28. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
    Plunkett W; Gandhi V; Huang P; Robertson LE; Yang LY; Gregoire V; Estey E; Keating MJ
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):2-12. PubMed ID: 8235690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of vorinostat: current applications and future perspectives for cancer therapy.
    Richon VM; Garcia-Vargas J; Hardwick JS
    Cancer Lett; 2009 Aug; 280(2):201-10. PubMed ID: 19181442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine].
    Furukawa H; Takahashi M; Nakajima M; Yamada T
    Nihon Rinsho; 2002 Aug; 60(8):1649-57. PubMed ID: 12187766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
    Gelmon KA; Eisenhauer EA; Harris AL; Ratain MJ; Workman P
    J Natl Cancer Inst; 1999 Aug; 91(15):1281-7. PubMed ID: 10433616
    [No Abstract]   [Full Text] [Related]  

  • 33. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Interleukin-21, new adjuvant for cancer therapy?].
    Iannello A; Ahmad A
    Med Sci (Paris); 2009 Apr; 25(4):341-3. PubMed ID: 19409182
    [No Abstract]   [Full Text] [Related]  

  • 35. Is response rate relevant to the phase II trial design of targeted agents?
    Dowlati A; Fu P
    J Clin Oncol; 2008 Mar; 26(8):1204-5. PubMed ID: 18285601
    [No Abstract]   [Full Text] [Related]  

  • 36. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
    Lang A; Graeven U
    Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
    [No Abstract]   [Full Text] [Related]  

  • 37. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.
    Inaba M; Maruyama E
    Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
    Adjei AA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Quinacrine Analogue Selective Against Gastric Cancer Cells: Insight from Biochemical and Biophysical Studies.
    Gomes A; Fernandes I; Teixeira C; Mateus N; Sottomayor MJ; Gomes P
    ChemMedChem; 2016 Dec; 11(24):2703-2712. PubMed ID: 27863116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease.
    Scoazec JY; Krolak-Salmon P; Casez O; Besson G; Thobois S; Kopp N; Perret-Liaudet A; Streichenberger N
    Ann Neurol; 2003 Apr; 53(4):546-7. PubMed ID: 12666126
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.